Andrew Cooper
Stock Analyst at Raymond James
(3.02)
# 1,217
Out of 5,150 analysts
151
Total ratings
43.28%
Success rate
0.16%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Maintains: Outperform | $35 → $45 | $25.13 | +79.07% | 3 | Nov 25, 2025 | |
| ITGR Integer Holdings | Reiterates: Outperform | $143 → $95 | $86.03 | +10.43% | 4 | Oct 24, 2025 | |
| HOLX Hologic | Downgrades: Market Perform | n/a | $75.67 | - | 13 | Oct 22, 2025 | |
| AVTR Avantor | Maintains: Outperform | $14 → $16 | $8.65 | +84.97% | 16 | Oct 16, 2025 | |
| HAE Haemonetics | Downgrades: Outperform | $105 → $78 | $64.67 | +20.61% | 10 | Aug 11, 2025 | |
| GH Guardant Health | Maintains: Outperform | $59 → $61 | $93.02 | -34.42% | 4 | Jul 31, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $98.49 | +16.76% | 9 | Jul 29, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $512.69 | +4.35% | 7 | Jul 24, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $5.28 | +89.39% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $13.99 | +78.70% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $203.99 | - | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $204.73 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $103.50 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $19.06 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $203.03 | -58.13% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $21.19 | +258.66% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $4.41 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.10 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $36.27 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.01 | - | 5 | Sep 22, 2021 |
Azenta
Nov 25, 2025
Maintains: Outperform
Price Target: $35 → $45
Current: $25.13
Upside: +79.07%
Integer Holdings
Oct 24, 2025
Reiterates: Outperform
Price Target: $143 → $95
Current: $86.03
Upside: +10.43%
Hologic
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $75.67
Upside: -
Avantor
Oct 16, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $8.65
Upside: +84.97%
Haemonetics
Aug 11, 2025
Downgrades: Outperform
Price Target: $105 → $78
Current: $64.67
Upside: +20.61%
Guardant Health
Jul 31, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $93.02
Upside: -34.42%
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $98.49
Upside: +16.76%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $512.69
Upside: +4.35%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $5.28
Upside: +89.39%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $13.99
Upside: +78.70%
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $203.99
Upside: -
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $204.73
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $103.50
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $19.06
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $203.03
Upside: -58.13%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $21.19
Upside: +258.66%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $4.41
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.10
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $36.27
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $3.01
Upside: -